These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36933492)

  • 1. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
    Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
    BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.
    Nguyen CTT; Van TNK; Huong PT
    Cancer Control; 2024; 31():10732748241285474. PubMed ID: 39285591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
    Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
    Zhang L; Chen C; Chai D; Li C; Guan Y; Liu L; Kuang T; Deng W; Wang W
    Front Immunol; 2022; 13():956533. PubMed ID: 36059512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Xu H; Cao D; Zhou D; Zhao N; Tang X; Shelat VG; Samant H; Satapathy SK; Tustumi F; Aprile G; He A; Xu X; Ge W
    BMC Cancer; 2023 Oct; 23(1):1006. PubMed ID: 37858207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.
    Ma D; Liu M; Zhai X; Li X; Jin B; Liu Y
    Front Immunol; 2023; 14():1215745. PubMed ID: 37520554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
    Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Liu Y; Pan J; Gao F; Xu W; Li H; Qi X
    Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of neutrophil/lymphocyte ratio and albumin/bilirubin grade as a prognostic predictor for hepatocellular carcinoma patients undergoing curative hepatectomy.
    Luo H; Huang C; Meng M; Zhang M; Li Z; Huang J
    BMC Gastroenterol; 2023 May; 23(1):162. PubMed ID: 37208618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.